| 11.14 0.39 (3.63%) | 08-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 13.85 | 1-year : | 15.63 |
| Resists | First : | 11.86 | Second : | 13.39 |
| Pivot price | 10.39 |
|||
| Supports | First : | 9.39 | Second : | 7.81 |
| MAs | MA(5) : | 10.59 |
MA(20) : | 10.61  |
| MA(100) : | 10.08 |
MA(250) : | 9.37 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 55.3 |
D(3) : | 45.8 |
| RSI | RSI(14): 55.4 |
|||
| 52-week | High : | 14 | Low : | 5.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FDMT ] has closed below upper band by 10.2%. Bollinger Bands are 28.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.3 - 11.33 | 11.33 - 11.37 |
| Low: | 10.49 - 10.53 | 10.53 - 10.58 |
| Close: | 11.07 - 11.13 | 11.13 - 11.2 |
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Thu, 06 Aug 2026
4D Molecular Therapeutics Inc (FDMT) Stock Price, Trades & News - GuruFocus
Wed, 05 Aug 2026
4D Molecular Therapeutics, Inc. (FDMT) insider sells 26,842 shares under plan - Stock Titan
Tue, 04 Aug 2026
4D Molecular Therapeutics (FDMT) Insider David Kirn Sells 12,415 Shares - GuruFocus
Tue, 04 Aug 2026
David Kirn Sells 12,415 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat
Tue, 04 Aug 2026
4D Molecular Therapeutics (FDMT) CEO sells 12,415 shares via 10b5-1 plan - Stock Titan
Tue, 04 Aug 2026
Enterprise value to revenue forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -69 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.228e+007 (%) |
| Held by Institutions | 3.905e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2853e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.57 |
| Profit Margin | -182.4 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 416.1 % |
| Return on Equity (ttm) | -21.5 % |
| Qtrly Rev. Growth | 8.824e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.7143e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -4.34 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 1.136e+007 |
| Forward Dividend | 1.293e+007 |
| Dividend Yield | 101975000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|